Shares of Aurobindo Pharma Limited touched a 52-week high of Rs 1,396.60 on the BSE on 20 April, rising 0.79% from the previous close of Rs 1,385.65, after the company secured two product approvals from the U.S. Food and Drug Administration.

The pharma firm received USFDA approval for Dextromethorphan Polistirex extended-release oral suspension (30 mg/5 mL, OTC), a cough relief formulation bioequivalent to its reference listed drug. The product will be manufactured at Unit-IV of APL Healthcare Private Limited, a wholly owned subsidiary of Aurobindo Pharma, with a planned launch in Q2 FY27.

In a separate approval, the USFDA cleared Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), bioequivalent to Ravicti Oral Liquid marketed by Horizon Therapeutics U.S. Holding LLC. This product will be manufactured at Unit-III of the company. Aurobindo Pharma plans an immediate market launch for this one.

On the financial front, Aurobindo Pharma reported standalone revenue of Rs 2,747.28 crore in Q3 FY26, with net profit coming in at Rs 582.07 crore for the quarter ended December 2025.

At 1:16 pm on BSE, shares were trading down by 1.14% at Rs 1,369.80, retreating from the session high. The stock’s 52-week range stands at Rs 1,017.00 to Rs 1,396.60.

Tired of missing hot stocks? Tradz by EquityPandit provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!